No Data
No Data
BofA Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $80
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Stifel Maintains Apogee Therapeutics(APGE.US) With Buy Rating
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $100
Apogee Therapeutics Completes Part A Enrollment for APG777 Phase 2 Trial Ahead of Schedule With 123 Patients Enrolled
Express News | Apogee Therapeutics Inc - Part a 16-Week Proof-of-Concept Data Expected Mid-2025